Evidence map›Paper›PMID 38068400›Full record

ReviewJournal of clinical medicine2023

Pathomechanisms of Diabetic Kidney Disease.

Satyesh K Sinha, Susanne B Nicholas

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Comparative Study ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Diabetic kidney disease, biomarkers, and finerenone.Diabetes, obesity & metabolism · 2026
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Inflammation and Diabetic Kidney Disease.International journal of molecular sciences · 2026
    Review
  17. Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Satyesh K SinhaDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Susanne B NicholasDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-3535-9120
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The worldwide occurrence of diabetic kidney disease (DKD) is swiftly rising, primarily attributed to the growing population of individuals affected by type 2 diabetes. This surge has been transformed into a substantial global concern, placing additional strain on healthcare systems already grappling with significant demands. The pathogenesis of DKD is intricate, originating with hyperglycemia, which triggers various mechanisms and pathways: metabolic, hemodynamic, inflammatory, and fibrotic which ultimately lead to renal damage. Within each pathway, several mediators contribute to the development of renal structural and functional changes. Some of these mediators, such as inflammatory cytokines, reactive oxygen species, and transforming growth factor β are shared among the different pathways, leading to significant overlap and interaction between them. While current treatment options for DKD have shown advancement over previous strategies, their effectiveness remains somewhat constrained as patients still experience residual risk of disease progression. Therefore, a comprehensive grasp of the molecular mechanisms underlying the onset and progression of DKD is imperative for the continued creation of novel and groundbreaking therapies for this condition. In this review, we discuss the current achievements in fundamental research, with a particular emphasis on individual factors and recent developments in DKD treatment.

Indexed as

hemodynamicinflammatory and fibrotic factorsmetabolicmineralocorticoid receptorosteopontinrenin angiotensin aldosterone systemtargeted therapies

Identifiers

PMID38068400
PMCPMC10707303
OpenAlexW4389044524

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.